



Cancelled before Active - Statement

Statement of Discontinuation of the study
Name of Sponsor: UCB Biopharma SPRL
Study No: 2016-000393-37
Product: bimekizumab
Title: A MULTICENTER, SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY/TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE INTRAVENOUS DOSES OF BIMEKIZUMAB (UCB4940) ADMINISTERED TO SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Phase: 2a
Study Period: NA
Centres: NA
Number of Subjects: 0
Publications: NA
Statement on discontinuation of the study: Discontinued during preparation of the trial. No participants entered the study, therefore no results / data are available.